Troriluzole: Clinical Trials

7 trials of Troriluzole, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 active not recruiting, 1 recruiting. 7 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 5, Active not recruiting 1, Recruiting 1
Phase 23Completed 2, Recruiting 1

Follow Troriluzole: new trials by email Literature Review of Troriluzole trials Research Report on Troriluzole

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder
Troriluzole, Placebo - Obsessive-Compulsive Disorder
Phase 3CompletedBiohaven Pharmaceuticals, Inc.5892021-01-292026-05-22
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Troriluzole, Placebo - Obsessive-Compulsive Disorder
Phase 3CompletedBiohaven Pharmaceuticals, Inc.4562020-12-222026-01-07
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide, Lomustine, Regorafenib - Glioblastoma
Phase 2 / Phase 3RecruitingGlobal Coalition for Adaptive Research22502019-07-302026-11-02
Troriluzole in Adult Participants With Spinocerebellar Ataxia
troriluzole, Placebo - Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1
Phase 3Active not recruitingBiohaven Pharmaceuticals, Inc.2992019-03-082026-06-24
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
Troriluzole, Placebo - Generalized Anxiety Disorder
Phase 3CompletedBiohaven Pharmaceuticals, Inc.8812019-02-192024-05-08
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
Troriluzole, Placebo - Obsessive-Compulsive Disorder
Phase 2 / Phase 3CompletedBiohaven Pharmaceuticals, Inc.4262017-12-192026-01-22
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
Troriluzole, Placebo - Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1
Phase 2 / Phase 3CompletedBiohaven Pharmaceuticals, Inc.1412016-12-152025-10-08

Conditions studied

Obsessive-Compulsive Disorder (3)  ·  Spinocerebellar Ataxias (2)  ·  Ataxia (1)  ·  Generalized Anxiety Disorder (1)  ·  Glioblastoma (1)  ·  Heart Arrest (1)  ·  Machado-Joseph Disease (1)  ·  Recurrence (1)  ·  Spinocerebellar Ataxia 10 (1)  ·  Spinocerebellar ataxia 8 (1)

Sponsors

Biohaven Pharmaceuticals, Inc. (6)  ·  Global Coalition for Adaptive Research (1)

Countries

United States (7)  ·  Canada (2)  ·  China (2)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Tim Cloughesy, MD (1)

Results publications

PMID 34115419, PMID 38773224, PMID 38814532, PMID 39806095, PMID 41980234